Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Entera Bio Ltd. (ENTX) been one of those stocks this year? A quick glance at the ...
Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet April 20, 2026 11:00 AM ...
Entera Bio ENTX makes oral peptide therapies, validating its disruptive N-Tab oral peptide proprietary technology platform. Its leading pipeline candidate is EB613, an oral, osteoanabolic (bone ...
(Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment ...
Entera Bio Ltd. (NASDAQ:ENTX), Orphazyme A/S (NASDAQ:ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) are among the biggest biopharma movers Wednesday. Entera Bio Climbs On Positive Data For ...
JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that ...
The Dow Jones gained by over 50 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around ...
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with ...
Last week Entera Bio (NASDAQ:ENTX) announced that it had taken what appears to be the final step before launching its Phase 3 registrational program for EB613, the first oral bone building tablet for ...
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results